ifinatamab deruxtecan + abiraterone

Ifinatamab deruxtecan + abiraterone is a combination under investigation for cancer therapy, combining an antibody-drug conjugate and an androgen biosynthesis inhibitor. **Ifinatamab deruxtecan** is a B7-H3–directed antibody-drug conjugate comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody (targeting the immunoregulatory protein B7-H3, overexpressed in several malignancies) linked to a potent topoisomerase I inhibitor payload (DXd/exatecan derivative) via a tetrapeptide-based cleavable linker. Its mechanism delivers the cytotoxic payload selectively to B7-H3–expressing cancer cells. **Abiraterone** is an oral small molecule that inhibits androgen biosynthesis by blocking CYP17A1, lowering androgen production in prostate cancer. The combination is being evaluated primarily for metastatic castration-resistant prostate cancer (mCRPC) and potentially other B7-H3–expressing cancers. Ifinatamab deruxtecan is developed by Daiichi Sankyo and Merck[1][5].